Literature DB >> 12638640

Advances in the use of naltrexone: an integration of preclinical and clinical findings.

Stephanie S O'Malley1, Janice C Froehlich.   

Abstract

Both preclinical and clinical studies are critical in the development of effective pharmacotherapeutic approaches for treating alcoholism. Nowhere has this been more evident than in the development of naltrexone for treating alcohol relapse. As studies continue on the use of naltrexone for modifying alcohol intake, promising avenues for continued work on maximizing the efficacy of naltrexone for treating alcohol abuse and alcoholism are emerging. Recent research suggests that naltrexone can influence key components of alcohol dependence, including loss of control over the decision to drink and the amount of alcohol consumed. Although not uniformly positive, the majority of clinical trials supports the hypothesis that naltrexone can reduce the urge to drink, increase the number of days abstinent, and minimize the risk of relapse to heavy drinking. Human laboratory and preclinical paradigms that have investigated how naltrexone alters patterns of drinking suggest that naltrexone treatment results in earlier cessation of drinking within a session. In addition, preclinical data suggest that the amount of alcohol consumed declines during subsequent sessions in the presence of naltrexone. Based on this analysis, future clinical trials should consider using analytic approaches that evaluate patterns of drinking (e.g., multiple event analysis) rather than single events (e.g., survival analysis). Furthermore, behavioral interventions and instructions can also be developed to take advantage of this effect. Additional preclinical and clinical work is warranted to identify dosing strategies that ensure adequate drug levels while reducing the possibility of developing tolerance to naltrexone. Finally, studies designed to identify the characteristics of drinking populations that are responsive to naltrexone and studies investigating the potential advantage of combining naltrexone with agents that alter a number of neurotransmitter systems are exciting new avenues of research. Ultimately, these lines for research promise to provide critical information that can be used to maximize the efficacy of naltrexone for treating alcoholism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12638640

Source DB:  PubMed          Journal:  Recent Dev Alcohol        ISSN: 0738-422X


  30 in total

1.  New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials.

Authors:  Ralitza Gueorguieva; Ran Wu; Brian Pittman; Joyce Cramer; Robert A Rosenheck; Stephanie S O'malley; John H Krystal
Journal:  Biol Psychiatry       Date:  2007-01-16       Impact factor: 13.382

2.  A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men.

Authors:  Jon Morgenstern; Alexis N Kuerbis; Andrew C Chen; Christopher W Kahler; Donald A Bux; Henry R Kranzler
Journal:  J Consult Clin Psychol       Date:  2012-05-21

3.  Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone.

Authors:  Janice C Froehlich; Brett J Hausauer; Dennis D Rasmussen
Journal:  Alcohol Clin Exp Res       Date:  2013-07-22       Impact factor: 3.455

4.  An Improved Antagonist Radiotracer for the κ-Opioid Receptor: Synthesis and Characterization of (11)C-LY2459989.

Authors:  Ming-Qiang Zheng; Su Jin Kim; Daniel Holden; Shu-fei Lin; Anne Need; Karen Rash; Vanessa Barth; Charles Mitch; Antonio Navarro; Michael Kapinos; Kathleen Maloney; Jim Ropchan; Richard E Carson; Yiyun Huang
Journal:  J Nucl Med       Date:  2014-05-22       Impact factor: 10.057

Review 5.  Ethanol consumption: how should we measure it? Achieving consilience between human and animal phenotypes.

Authors:  Robert F Leeman; Markus Heilig; Christopher L Cunningham; David N Stephens; Theodora Duka; Stephanie S O'Malley
Journal:  Addict Biol       Date:  2010-04       Impact factor: 4.280

6.  Varenicline Reduces Alcohol Intake During Repeated Cycles of Alcohol Reaccess Following Deprivation in Alcohol-Preferring (P) Rats.

Authors:  Janice C Froehlich; Emily R Nicholson; Julian E Dilley; Nick J Filosa; Logan C Rademacher; Teal N Smith
Journal:  Alcohol Clin Exp Res       Date:  2017-07-10       Impact factor: 3.455

7.  Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism.

Authors:  Janice C Froehlich; Stephen M Fischer; Julian E Dilley; Emily R Nicholson; Teal N Smith; Nick J Filosa; Logan C Rademacher
Journal:  Alcohol Clin Exp Res       Date:  2016-07-29       Impact factor: 3.455

8.  Alcohol Drinking and Blood Alcohol Concentration Revisited.

Authors:  Julian E Dilley; Emily R Nicholson; Stephen M Fischer; Robin Zimmer; Janice C Froehlich
Journal:  Alcohol Clin Exp Res       Date:  2017-12-13       Impact factor: 3.455

Review 9.  Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.

Authors:  Richard L Bell; Helen J K Sable; Giancarlo Colombo; Petri Hyytia; Zachary A Rodd; Lawrence Lumeng
Journal:  Pharmacol Biochem Behav       Date:  2012-07-25       Impact factor: 3.533

10.  Alcohol enhances HIV infection of cord blood monocyte-derived macrophages.

Authors:  Dimitrios S Mastrogiannis; Xu Wang; Min Dai; Jieliang Li; Yizhong Wang; Yu Zhou; Selin Sakarcan; Juliet Crystal Pena; Wenzhe Ho
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.